We aspire, as part of our vision, to be a trusted leader in changing the practice of medicine. To realize this vision, we need to earn and maintain the trust of patients, associates, healthcare partners, shareholders and the society we serve.
We recognize that society’s expectations of our industry and of Novartis are changing and that we must go beyond just doing what is legal in order to meet legitimate societal expectations.
Our aim is to prevent issues from occurring, drive personal accountability for behaviors, and generate learnings that can be applied across the organization.
In August 2014, we created a new position of Chief Ethics and Compliance Officer, reporting to the CEO – elevating the Compliance function to the highest levels in the company. On May 1, 2016, Shannon Klinger, formerly General Counsel for Sandoz, was appointed as Novartis Chief Ethics & Compliance Officer and Head Litigation. Shannon continues to strengthen our commitment to integrity and compliance and embed a culture of high performance with integrity throughout the organization.
We do not tolerate unethical behavior by our associates anywhere, and we will take all necessary steps to ensure compliance with our Code of Conduct and all applicable laws. At the same time, we know there are potential pockets of bad behavior in a global business with more than 120 000 associates, and we work to take swift action when this occurs.
To ensure accountability of local country organizations, our management includes integrity and compliance questions as part of standard business reviews. We work to identify and mitigate risk exposure proactively so it can be reviewed and discussed at a management level.
Our goal is to maintain consistent standards of business practices across Novartis, ultimately enabling us to provide the best possible care for patients globally.